每經AI快訊，南微醫學（SH 688029，收盤價(jia)：95.11元）11月9日(ri)(ri)(ri)晚間(jian)發布(bu)公(gong)(gong)告(gao)(gao)稱，截至本(ben)公(gong)(gong)告(gao)(gao)日(ri)(ri)(ri)，Huakang Limited持(chi)(chi)(chi)有(you)南微醫學科(ke)技股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)有(you)限公(gong)(gong)司(si)(si)(si)(si)約2373萬(wan)(wan)(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)，占(zhan)公(gong)(gong)司(si)(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)的(de)(de)約12.67%。相(xiang)關股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)來源為公(gong)(gong)司(si)(si)(si)(si)首次(ci)公(gong)(gong)開(kai)發行股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)票并上市前取得(de)的(de)(de)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)，及該等股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)于(yu)公(gong)(gong)司(si)(si)(si)(si)2022年實施(shi)資本(ben)公(gong)(gong)積轉增(zeng)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)時獲得(de)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)，相(xiang)關股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)已(yi)于(yu)2022年7月22日(ri)(ri)(ri)起(qi)(qi)上市流通(tong)。公(gong)(gong)司(si)(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)東Huakang Limited因自身資金(jin)需求，擬(ni)通(tong)過(guo)(guo)(guo)(guo)上海證券交(jiao)(jiao)易(yi)(yi)所(suo)交(jiao)(jiao)易(yi)(yi)系統以集中(zhong)競(jing)價(jia)、大宗交(jiao)(jiao)易(yi)(yi)方式減(jian)(jian)(jian)持(chi)(chi)(chi)公(gong)(gong)司(si)(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)合計(ji)不(bu)超過(guo)(guo)(guo)(guo)約562萬(wan)(wan)(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)，其(qi)中(zhong)擬(ni)通(tong)過(guo)(guo)(guo)(guo)證券交(jiao)(jiao)易(yi)(yi)所(suo)集中(zhong)競(jing)價(jia)交(jiao)(jiao)易(yi)(yi)方式進行減(jian)(jian)(jian)持(chi)(chi)(chi)的(de)(de)，將于(yu)減(jian)(jian)(jian)持(chi)(chi)(chi)計(ji)劃公(gong)(gong)告(gao)(gao)披(pi)露之日(ri)(ri)(ri)起(qi)(qi)15個(ge)交(jiao)(jiao)易(yi)(yi)日(ri)(ri)(ri)之后的(de)(de)90日(ri)(ri)(ri)內(nei)減(jian)(jian)(jian)持(chi)(chi)(chi)公(gong)(gong)司(si)(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)不(bu)超過(guo)(guo)(guo)(guo)約187萬(wan)(wan)(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)，且任意連(lian)續(xu)90個(ge)自然(ran)(ran)日(ri)(ri)(ri)內(nei)通(tong)過(guo)(guo)(guo)(guo)交(jiao)(jiao)易(yi)(yi)所(suo)集中(zhong)競(jing)價(jia)方式減(jian)(jian)(jian)持(chi)(chi)(chi)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)的(de)(de)總(zong)(zong)數(shu)(shu)，不(bu)超過(guo)(guo)(guo)(guo)公(gong)(gong)司(si)(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)總(zong)(zong)數(shu)(shu)的(de)(de)1%；擬(ni)通(tong)過(guo)(guo)(guo)(guo)大宗交(jiao)(jiao)易(yi)(yi)方式減(jian)(jian)(jian)持(chi)(chi)(chi)的(de)(de)，將于(yu)本(ben)減(jian)(jian)(jian)持(chi)(chi)(chi)計(ji)劃披(pi)露之日(ri)(ri)(ri)起(qi)(qi)3個(ge)交(jiao)(jiao)易(yi)(yi)日(ri)(ri)(ri)之后的(de)(de)90日(ri)(ri)(ri)內(nei)減(jian)(jian)(jian)持(chi)(chi)(chi)公(gong)(gong)司(si)(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)不(bu)超過(guo)(guo)(guo)(guo)約374萬(wan)(wan)(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)，且任意連(lian)續(xu)90個(ge)自然(ran)(ran)日(ri)(ri)(ri)內(nei)通(tong)過(guo)(guo)(guo)(guo)大宗交(jiao)(jiao)易(yi)(yi)方式減(jian)(jian)(jian)持(chi)(chi)(chi)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)總(zong)(zong)數(shu)(shu)不(bu)超過(guo)(guo)(guo)(guo)公(gong)(gong)司(si)(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)總(zong)(zong)數(shu)(shu)的(de)(de)2%。本(ben)次(ci)擬(ni)通(tong)過(guo)(guo)(guo)(guo)以上兩(liang)種方式減(jian)(jian)(jian)持(chi)(chi)(chi)的(de)(de)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)合計(ji)不(bu)超過(guo)(guo)(guo)(guo)公(gong)(gong)司(si)(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)比例3%。若減(jian)(jian)(jian)持(chi)(chi)(chi)期間(jian)公(gong)(gong)司(si)(si)(si)(si)有(you)送股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)、資本(ben)公(gong)(gong)積金(jin)轉增(zeng)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)等股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)變動事項，減(jian)(jian)(jian)持(chi)(chi)(chi)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)數(shu)(shu)量進行相(xiang)應(ying)調(diao)整。

2021年1至12月份(fen)，南微醫學(xue)的(de)營業(ye)收入構成(cheng)為(wei)：醫療器械占比99.76%。

南微(wei)醫學(xue)的董事長是(shi)隆(long)曉(xiao)輝，男，63歲，學(xue)歷(li)(li)背景為碩士(shi)；總經(jing)理是(shi)冷德(de)嶸(rong)，男，59歲，學(xue)歷(li)(li)背景為本科。

截至發稿，南微醫(yi)學市值為178億元(yuan)。

道(dao)達號(hao)（daoda1997）“個股趨勢(shi)”提醒：
1. 近30日內共有1批機構對南微醫學調研，合計調研的機構家數為116家；
2. 南微醫學上次發布減持公告是2022年11月04日，第二個交易日下跌2.27%，南微醫學近一年共發布8次減持類公告。
更多個股(gu)趨勢信息，請(qing)搜索微信公眾號“道達號”，回復“查詢”，領取免費(fei)查詢權限(xian)！

每經頭條(tiao)（nbdtoutiao）——

(記者 王瀚黎)

免責聲明：本文內容與數(shu)據僅供參考，不構成投資建(jian)議，使用前請核實。據此操(cao)作(zuo)，風險自(zi)擔。